Company Overview and News
Gold prices remained range-bound but above the immediate-term trend line on Thursday as a mixture of news, both good and bad, kept the metal under its 3-month trading range ceiling. On a more positive note, however, silver outperformed and is finally showing signs of strengthening after months of lagging gold. In this report we’ll examine gold’s near-term rally prospects as its window of opportunity for doing so remains open for now but is fast closing.
Renewed expectations of higher inflation amid some strength in the U.S. economy and the resultant rise in interest rates may add to the gains in the beleaguered greenback in the short term. This may not be a great situation for gold investing but investors can pile up on silver in any case.
As if investors don't have enough incentives for safety purchases of the yellow metal, they just got another one over the weekend. The U.S.-led air strike on Syria in retaliation for the apparent use of chemical weapons by that country was the latest event which should stimulate additional interest in gold. In today's report we'll examine gold's improving psychological backdrop in light of the latest geopolitical uncertainties as we see that gold's immediate-term uptrend remains intact.
As you may know, I tend to write a SLV Weekly every week. Unfortunately, I was quite busy in March, working on different projects, most notably on the base metals complex - I was due to speak at a conference on copper in Madrid and on zinc and lead in London.
After spending the last few weeks in a lackluster sideways trend, the gold price is finally showing signs of life again after last week's brief scare. Encouragingly, gold showed strength on Tuesday even despite a lifting of the "fear factor." As we'll discuss here, the fact that gold is rallying without a sustained fear component is even better for its intermediate-term prospects.
Just when it looked like gold's support was gone, back comes the safety bid as the fear factor returned last week. Renewed concerns over domestic trade policy and its possible impact on the U.S. economy put gold back into the spotlight last Friday. In today's comments I'll make the case for an upside resolution to gold's lateral trend at some point in March. We'll also examine some factors which would boost the odds of a gold turnaround this month in our latest discussion of the near-term outlook.
The downswing in the gold price (NYSE:GLD) yesterday should definitely put swing traders on alert that lower prices are coming. Gold now is in clear danger of breaking though the lows its printed on the 9th of February last which was clearly a daily cycle low in my opinion. Why? Well the present intermediate cycle kicked offed proceedings on the 11th of December last year. Therefore the 9th of February last was 2 calendar months or roughly 30 to 40 trading days (which is typical daily cycle length) since the intermediate bottom back in December.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET